HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
Keyword(s):
HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are currently multiple clinical trials, by HUYABIO International, to test the efficacy of HBI-8000 in monotherapy or in combination settings in leukemias and in solid tumors. The current review is focused on the applications of HDACi HBI-8000 in cancer therapy and its potential in combination with DDR agents.
2013 ◽
Vol 19
(15)
◽
pp. 4262-4272
◽
2008 ◽
Vol 14
(3)
◽
pp. 804-810
◽
2012 ◽
Vol 69
(6)
◽
pp. 1413-1422
◽
2014 ◽
Vol 11
(4)
◽
pp. 2908-2912
◽
2013 ◽
2013 ◽